

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zhongzhi Pharmaceutical Holdings Limited**

**中智藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3737)**

### **POSITIVE PROFIT ALERT**

This announcement is made by the board of directors (the “**Board**”) of Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (“**FP2023**”), it is expected that the Group will record a significant increase of around 70% in the net profit for FP2023 as compared with the corresponding period in 2022.

The expected increase in the net profit of the Group is mainly attributable to (i) the increase in demand for the Company’s Chinese patent medicine and cell-wall broken decoction pieces with the continuous increasing health awareness of the public; and (ii) an improvement in the overall control of operational efficiency.

The information set out in this announcement is only based on the information currently available to the Board and the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for FP2023. The unaudited consolidated results of the Group for FP2023 are expected to be announced by the Company before the end of August 2023. Shareholders and potential investors are advised to read the interim results announcement of the Company when it is published.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Zhongzhi Pharmaceutical Holdings Limited**  
**Mr. Lai Zhi Tian**  
*Chairman*

Hong Kong, 19 July 2023

*As at the date of this announcement, the Board comprises nine directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive directors are Ms. Jiang Li Xia and Mr. Peng Zhiyun. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.*